Global private equity and venture capital news and research

Posts Tagged ‘Aisling Capital’

15 March 2016

KKR leads $45m round in medical device company Spirox

smile-191626_960_720 Global private equity giant KKR has led a $45m Series C financing round in medical device company Spirox.

21 April 2015

Venrock co-leads $18.5m Series B for nasal device maker Spirox

face-melt-631325-m Venture capital investors Venrock and Aisling Capital have led a $18.5m Series B funding round for nasal medical device maker Spirox.

28 October 2014

Syros lands $53m from eight VC firms

pills-pills-pills-4-606633-m Eight venture capital firms have participated in a $53m Series B financing round for gene control therapies company Syros Pharmaceuticals.

8 May 2014

NEA joins Aisling, OrbiMed to back cancer treatment business Loxo with $24m

life science test tube_sq Venture capital major New Enterprise Associates has led a $24m Series B financing round for cancer-focused biopharmaceutical business Loxo Oncology.

24 March 2014

Venture capital-backed Versartis soars after IPO

Venture capital-backed Versartis soars after IPO

18 December 2013

Cancer treatment company ViewRay secures $30m

mri Medical devices company ViewRay has raised a $30m round, which was backed by new investor Cowealth Medical Holding.

8 October 2013

Sofinnova Ventures leads $20m Series D for biotech company Versartis

biotech_lrg Sofinnova Ventures has led a $20m Series D round for Versartis to help the biotech company prepare for an international Phase 3 pediatric trial of VRS-317, a treatmet for patients with growth hormone deficiency.

3 October 2013

Lensar interest heats up with new $87 debt, equity investments

A trio of venture capital investors have backed laser cataract surgery business Lensar with $27m of equity financing.

12 June 2013

Swift part-exit for Longitude as Esperion eyes IPO weeks after investment $

Venture investors in biopharmaceutical business Esperion Therapeutics are preparing to sell down their stakes through an IPO just weeks after the company completed a $33m preferred financing round.

6 November 2012

US biopharma Ambit Biosciences nets $25m tranche of $50m financing

US biopharmaceutical company Ambit Biosciences has closed the first $25m tranche of a new $50m preferred stock financing, led by existing investor OrbiMed Advisors.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016